Drug-Eluting Stents (DES): A Comprehensive Guide for Cardiology
DES = Drug-Eluting Stent – a coronary or peripheral stent coated with an antiproliferative drug (sirolimus, everolimus, zotarolimus) embedded in a polymer matrix.
Mechanism
Local drug elution inhibits smooth muscle cell proliferation and migration, reducing neointimal hyperplasia and in-stent restenosis (ISR).
Generations
- 1st gen: Cypher (sirolimus), Taxus (paclitaxel) – durable polymers, higher late thrombosis.
- 2nd gen: Xience (everolimus), Promus – biocompatible polymers, thinner struts.
- 3rd gen: Bioabsorbable polymer (Synergy, Orsiro) or polymer-free (BioFreedom) – improved healing.
Indications
- Coronary artery disease (stable angina, ACS)
- Peripheral artery disease (femoropopliteal, below-knee)
Key Consideration
Requires dual antiplatelet therapy (DAPT) (aspirin + P2Y12 inhibitor) for 6–12 months (per guidelines) to prevent stent thrombosis.
Cardiovascular Disease - Related Articles
- Endovenous Ablation for Varicose Veins: Treatment & Procedure
- Heart Palpitations: Causes, Symptoms & When to Worry
- Understanding Long-Term Plavix Use: Benefits and Considerations
- Arteries vs. Veins: Key Similarities and Differences
- Graco Bebe Sounds Prenatal Heart Listener: User Manual & Instructions
- Blood Pressure 189/120 mm Hg: Hypertensive Crisis – Act Immediately
- Understanding Chest Pain and Mitral Valve Prolapse (MVPS)
